Drugs / anti-MESO CAR-T cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03814447 | Aug 2019 → Jan 2023 | ovarian cancer | Shanghai 6th People's Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03799913 | Apr 2019 → Oct 2021 | ovarian cancer | Zhejiang University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04981691 | Oct 2021 → Jan 2022 | refractory malignant neoplasm | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03916679 | Apr 2019 → Apr 2022 | ovarian cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti- MESO CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03814447 ↗ |
| Modality | Cell therapy | “Retroviral vector-transduced autologous T cells to express anti-MESO CARs” NCT03799913 ↗ |
| Route | Intravenous | “intravenous (IV) mRNA electroporated fully-humanized anti-MESO re-directed autologous T cell administration” NCT04981691 ↗ |